← 返回

基于谷氨酰胺代谢预测肺腺癌的预后、免疫原性和免疫治疗疗效

英文原题:Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.

查看英文原题

Prediction of prognosis, immunogenicity and efficacy of immunotherapy based on glutamine metabolism in lung adenocarcinoma.

PubMed 2022/08/11(内容时间) Front Immunol Q1 · IF 7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

本研究发现,基于 Gln 代谢的模型在预测肺癌预后和免疫治疗疗效方面发挥了重要作用。我们进一步表征了 TME 的 Gln 代谢,并研究了 Gln 代谢相关基因 EPHB2,为靶向 Gln 代谢的抗肿瘤策略提供了理论框架。

研究思路结论见上方概要

谷氨酰胺(Gln)代谢已被报道在癌症中发挥重要作用。然而,其在肺腺癌中作用的全面分析仍不可得。本研究建立了一个新的Gln代谢量化系统,以预测肺癌的预后和免疫治疗疗效。此外,还表征了肿瘤微环境(TME)中的Gln代谢,并确定了Gln代谢相关基因用于靶向治疗。

我们基于73个Gln代谢相关基因,全面评估了513例肺腺癌(LUAD)患者的Gln代谢模式。基于差异表达基因(DEGs),利用Cox回归和Lasso回归分析构建了风险模型。该模型的预后效能通过来自山东省立医院的独立LUAD队列、来自GEO的整合LUAD队列以及来自TCGA数据库的泛癌队列进行了验证。使用五个独立的免疫治疗队列验证该模型在预测免疫治疗疗效方面的性能。接下来,使用一系列单细胞测序分析来表征TME中的Gln代谢。最后,使用单细胞测序分析、转录组测序以及一系列体外实验来探索EPHB2在LUAD中的作用。

LUAD患者最终被分为低风险组和高风险组。低风险组患者的特征为Gln代谢水平低、具有生存优势、“热”免疫表型以及从免疫治疗中获益。与其他细胞相比,TME中的肿瘤细胞表现出最活跃的Gln代谢。在免疫细胞中,肿瘤浸润性T细胞表现出最活跃的Gln代谢水平,尤其是CD8 T细胞耗竭和Treg抑制。EPHB2作为该模型中的关键基因,被证明可促进LUAD细胞增殖、侵袭和迁移,并调控Gln代谢通路。最后,我们发现EPHB2在巨噬细胞中高表达,尤其是M2巨噬细胞。它可能参与巨噬细胞的M2极化,并介导M2巨噬细胞对NK细胞的负向调控。

展开英文摘要原文

Glutamine (Gln) metabolism has been reported to play an essential role in cancer. However, a comprehensive analysis of its role in lung adenocarcinoma is still unavailable. This study established a novel system of quantification of Gln metabolism to predict the prognosis and immunotherapy efficacy in lung cancer. Further, the Gln metabolism in tumor microenvironment (TME) was characterized and the Gln metabolism-related genes were identified for targeted therapy.

We comprehensively evaluated the patterns of Gln metabolism in 513 patients diagnosed with lung adenocarcinoma (LUAD) based on 73 Gln metabolism-related genes. Based on differentially expressed genes (DEGs), a risk model was constructed using Cox regression and Lasso regression analysis. The prognostic efficacy of the model was validated using an individual LUAD cohort form Shandong Provincial Hospital, an integrated LUAD cohort from GEO and pan-cancer cohorts from TCGA databases. Five independent immunotherapy cohorts were used to validate the model performance in predicting immunotherapy efficacy. Next, a series of single-cell sequencing analyses were used to characterize Gln metabolism in TME. Finally, single-cell sequencing analysis, transcriptome sequencing, and a series of in vitro experiments were used to explore the role of EPHB2 in LUAD.

Patients with LUAD were eventually divided into low- and high-risk groups. Patients in low-risk group were characterized by low levels of Gln metabolism, survival advantage, "hot" immune phenotype and benefit from immunotherapy. Compared with other cells, tumor cells in TME exhibited the most active Gln metabolism. Among immune cells, tumor-infiltrating T cells exhibited the most active levels of Gln metabolism, especially CD8 T cell exhaustion and Treg suppression. EPHB2, a key gene in the model, was shown to promote LUAD cell proliferation, invasion and migration, and regulated the Gln metabolic pathway. Finally, we found that EPHB2 was highly expressed in macrophages, especially M2 macrophages. It may be involved in the M2 polarization of macrophages and mediate the negative regulation of M2 macrophages in NK cells.

This study revealed that the Gln metabolism-based model played a significant role in predicting prognosis and immunotherapy efficacy in lung cancer. We further characterized the Gln metabolism of TME and investigated the Gln metabolism-related gene EPHB2 to provide a theoretical framework for anti-tumor strategy targeting Gln metabolism.

论文信息

作者
Liu J、Shen H、Gu W、Zheng H、Wang Y、Ma G、Du J
单位
Institute of Oncology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.China
文献类型
非美国政府资助研究
期刊
Frontiers in immunology2022
原文标识
PubMed 36032135 · DOI 10.3389/fimmu.2022.960738